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ABSTRACT 
Introduction: Staphylococcus aureus is a virulent bacterial pathogen which is associated 
with considerable morbidity and mortality. There are relatively few studies describing 
invasive S. aureus infections in children, particularly in developing countries.  
Objectives: To define the spectrum of clinical presentation, risk factors, duration of 
treatment and outcomes of paediatric S. aureus infections treated at Chris Hani 
Baragwanath Academic Hospital (CHBAH), South Africa. 
Methods: A retrospective, descriptive study for the period from January to December 
2013 was conducted. Data were sought for all children <14 years of age with S. aureus 
infection. 
Results: Four hundred, twenty-two episodes of S. aureus infection were identified. 
Clinical data were obtained for 286 (68%) cases, on which all further analyses were 
based. Two-hundred, twenty-six (79%) infections were caused by methicillin-
susceptible S. aureus (MSSA), and 60 (21%) were caused by methicillin-resistant S. 
aureus (MRSA). Clinical presentations for MSSA bacteraemia included skin and soft 
tissue infection (45%), pneumonia (10%), meningitis (7%), bone/joint infections (5%) 
and urinary tract infections (4%). Risk factors for MRSA sepsis included burns (OR 
38.01; 95%CI 15.33-94.21), prematurity (OR 14.42; 95%CI 5.72-36.34), prolonged 
hospitalisation (OR 12.26; 95%CI 3.81-40.77), presence of indwelling device (OR 12.08; 
95%CI 5.86-24.90) and malnutrition (OR 11.03; 95%CI 3.41-35.74). Five cases of MRSA 
were attributed to have been community-acquired.  
Conclusion: Paediatric S. aureus infections are an important cause of morbidity. Most 
invasive S. aureus infections are caused by methicillin-susceptible strains, although 
MRSA should be considered particularly in the context of hospitalised patients.  
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CHAPTER 1 
1.0 INTRODUCTION 
Staphylococcus aureus is a virulent pathogen, which can be associated with considerable 
morbidity and mortality. Among Gram-positive bacteraemias, S. aureus bacteraemia 
(SAB) is one of the most prevalent and difficult to treat infections (1). Most studies have 
been performed in adults but little is known about bloodstream and other infections due 
to S. aureus in children, particularly in developing countries (2).  
 
A study conducted in Birmingham, United Kingdom, found that SAB in the paediatric 
population was significantly different to SAB in the adult population, with more 
similarities to the clinical spectrum of disease as encountered in the neonatal group (3).  
 
Staphylococcus aureus produces disease in two main ways (2). Production of toxins leads 
to specific diseases such as acute gastroenteritis, staphylococcal scalded skin syndrome 
(SSSS), and staphylococcal toxic shock syndrome (STSS), while direct tissue invasion 
causes localized folliculitis, abscesses, cellulitis, pyomyositis, osteomyelitis, and septic 
arthritis (2). Severe infection can present as overt septicaemia occasionally followed by 
disseminated secondary infection, including pneumonia, infective endocarditis, and 
meningoencephalitis (2). 
 
Infections caused by S. aureus are often classified in terms of the clinical isolate’s 
antibiotic susceptibility profile as being either methicillin-sensitive (MSSA) or 
methicillin-resistant (MRSA). MRSA infection can be separated into two major 
categories: community-acquired or hospital-acquired (4). According to the Centers for 
Disease Control and Prevention, patients need to fulfil several criteria before the 
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clinician can identify an MRSA infection as being community-acquired in nature (4). 
Firstly, patients cannot have any medical devices or indwelling catheters that are 
permanently placed through their skin, and must not have any medical history of MRSA 
infection (4). Also, patients cannot have any history of a recent hospitalization, or be 
resident in a nursing home or other long-term care facility (4).Furthermore, the MRSA 
infection must be diagnosed in the outpatient environment, or the positive culture for 
MRSA must be identified within 48 hours of hospital admission (4). 
  
Community-acquired MRSA (CA-MRSA) strains are associated with greater toxin 
production, compared with nosocomial MRSA strains (5).Many CA-MRSA strains carry 
the Panton-Valentine leucocidin (PVL) genes, which encode cytotoxins that can cause 
tissue necrosis and leukocyte destruction (5).  
 
 
1.1 EPIDEMIOLOGY OF PAEDIATRIC S. AUREUS INFECTION  
Two recent South African studies, conducted in Soweto and Cape Town, have described 
the epidemiology of S. aureus bacteraemia in children. The first study was a 
retrospective review of children hospitalized with S. aureus bacteraemia at Chris Hani 
Baragwanath Academic Hospital (CHBAH), Soweto, between January 2005 and 
December 2006 (6). The main focus of that study was community-onset S. aureus 
bacteraemia, and it therefore did not include hospital-acquired isolates (6). One hundred  
sixty-one episodes of community-onset S. aureus bacteraemia were identified, with an 
incidence of 26/100 000 (6). Sixty-three (39%) of the 161 isolates were identified as 
MRSA, with an incidence if 10/100 000 (6). 
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At Red Cross War Memorial Children’s Hospital (RCWMCH) in Cape Town, between 
January 2007 and December 2011, 365 episodes of S. aureus bacteraemia were 
identified (7). Two-hundred, seventy(74%) had MSSA and 95 (26%)had MRSA (7). The 
annual incidence of SAB in Cape Town was 3.28/1000 hospital admissions per year, 
with a mean frequency of 2.43 MSSA cases and 0.85 MRSA cases per 1000 hospital 
admissions per year (7). The place of acquisition of  SAB was identifiable in 357/365 
(97.8%) episodes; 33% were nosocomial, 16% healthcare associated and 51% 
community-acquired (7). 
 
An Australian study, conducted in Sydney, described 431 patients with community-
associated S. aureus infection that were hospitalised in 2008 (8). Of the 431 
patients,19.3%  had MRSA (8).  The findings of the Australian study are similar to the 
South African studies, which showed a predominant occurrence of MSSA in the 
paediatric group, which was not the case in the adult and neonatal groups (7, 8).  
 
The rates of MRSA have been on an upward trend in these studies, ranging between 10% 
and 24% (3, 6, 7), with a rise in the incidence of nosocomial SAB described in Cape Town 
accounting for approximately half of all cases of MRSA SAB in that study (7). 
 
1.2 SPECTRUM OF CLINICAL PRESENTATION 
Most cohorts of S. aureus infection in children reveal that bone and joint infections, 
followed by skin and soft tissue infections (SSTI), are the commonest clinical 
presentations (9). A study from New Zealand found that SSTI occurred in two thirds of 
children presenting with S. aureus infection (10).  This finding was different from the 
South African studies. 
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In the study from Cape Town, SAB without an identifiable source was the most 
frequently encountered staphylococcal syndrome (33%), followed by pneumonia with 
or without empyema (22%) (7). Out of 365 patients at RCWMCH, 17% presented with 
SSTI, and 12% presented with bone and joint infections. MRSA infections were mainly 
responsible for SAB without an identifiable source, while bone and joint infections were 
more likely to be due to MSSA (7). Furthermore, all central venous catheter-related line 
infections were of nosocomial origin and were equally likely to be attributable to MSSA 
or MRSA (7).  
 
In Soweto, there were no statistically significant differences in clinical presentation 
between MRSA and MSSA (6).The most common diagnoses were pneumonia (35%), 
gastroenteritis (21%), sepsis (16%), and primary bloodstream infections without a 
focus (10%) (6). 
 
One of the most dreaded complications of SAB is infective endocarditis, which has been 
reported to occur in 6-32% of patients from whom S. aureus is isolated in blood cultures 
(11). The presenting symptoms and clinical findings are non-specific, so it is advisable 
that echocardiography should be considered as part of the routine evaluation of SAB 
patients (11). 
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1.3 CHARACTERISTICS OF PATIENTS WITH S. AUREUS INFECTION 
At RCWMCH, the median age of patients with SAB was 11 months (7). Neonates 
accounted for 10% of episodes and infants represented 52% of paediatric SAB cases (7). 
In contrast to this, in a Canadian study of paediatric SAB, the median age of patients was 
6.6 years (IQR 1.0 to 11.2 years) (9).  
 
In most studies of paediatric S. aureus infection, children with MRSA were significantly 
younger than those with MSSA (7, 12, 13). Neonates were more likely to have MRSA as 
compared to the older children(3). 
 
In New Zealand, males accounted for 60% of cases of SAB, which was similar to the 52% 
males at RCWMCH (7, 10). At RCWMCH, children with MRSA were frequently underweight, 
stunted and HIV infected (7). 
 
1.4 RISK FACTORS FOR S. AUREUS INFECTION 
Comorbid conditions that are associated with SAB include congenital heart disease, 
malignancy and chronic skin disorders (3, 9). Malnutrition and HIV infection were also 
found to be risk factors for SAB, as described in Kenya and South Africa (Cape Town) (2, 7, 
14).With regards to age group, infants were found to be at higher risk of SAB, as 
compared to older children (3, 7).  
 
1.4.1 RISK FACTORS FOR INFECTION WITH MRSA  
Malnutrition and HIV infection have been identified as risk factors for both SAB and 
MRSA (2, 7, 14). HIV-infected children were found to be at higher risk for MRSA in Kenya 
and South Africa (2, 7).This was thought to be likely due to frequent hospitalization of 
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HIV-infected children, resulting in an increased risk of colonisation with hospital-
acquired pathogens and hospital-acquired infections (14). 
 
Other comorbid conditions that were found to be risk factors for MRSA were congenital 
heart disease and concurrent tuberculosis (7). Infants were not only at higher risk of SAB 
in general, but also at higher risk of MRSA (3, 7). 
 
Prolonged hospitalization and residents of long-term facilities were also found to be 
significant risk factors for MRSA (7). 
 
The presence of an indwelling device, particularly a central venous catheter, was the 
most commonly identified risk factor for MRSA infection in South Africa and the United 
Kingdom (3, 7). 
 
1.5 RISK FACTORS FOR MORTALITY 
MRSA was found to be the most significant risk factor associated with a high mortality 
rate amongst children with SAB in South Africa and in  the United Kingdom (7, 12). 
Infective endocarditis has also been identified as a risk factor for mortality, particularly 
in children <10 years of age (15). In a study from Kenya, children with no identified focus 
of SAB had a higher risk of mortality as compared to those with a focus of infection (2). 
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1.6 MANAGEMENT OF S. AUREUS INFECTIONS 
 Site of infection and clinical severity should guide the clinician regarding antibiotic 
choice, route and duration of therapy, and the need for additional interventions. For 
example, S. aureus bone and joint infections have proven to be difficult to treat, usually 
involving a prolonged course of antibiotics, often with surgical intervention (5). 
 
The Infectious Diseases Society of America recommends systemic antibiotic treatment in 
addition to incision and drainage in patients with skin abscesses who have severe or 
extensive disease, including: rapid disease progression, associated cellulitis, signs and 
symptoms of systemic illness, associated coexisting conditions or immunosuppression, 
very young or advanced age, an abscess in an area that is difficult to drain, associated 
phlebitis, or an abscess that does not respond to incision and drainage alone (16). 
 
It is recommended that bone and joint infections are treated for a longer duration, 
approximately 6-7weeks (13).  
 
At RCWMCH, infective endocarditis, bone or joint infections, and pulmonary infections 
were treated for a median of 44 days (IQR 39-51 days), 40 days (IQR 32-79 days) and 13 
days (IQR 7-23 days)  respectively  (7). Overall, the duration of treatment for all the other 
clinical presentations of S. aureus infections was 14 days (IQR 7-29 days) (7).  
 
Recommendations from the Infectious Diseases Society of America are that MRSA 
bacteraemia should be treated for at least 14 days in the absence of any complicating 
factors (16).  
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In addition to antimicrobial therapy, a population-based study recently endorsed 
recommendations that chest tube drainage is an acceptable first treatment option for 
most children with empyema (17).  
 
At CHBAH, the current treatment for bone and soft tissue infections includes cloxacillin, 
cefotaxime and the consideration of fusidic acid. Children are investigated by means of 
bone scan and echocardiograph if SAB persists despite adequate antibiotics; this is 
according to the 2006 guidelines for the hospital. 
 
1.7 ANTIMICROBIAL SUSCEPTIBILITY 
Most South African studies have looked at antimicrobial susceptibility of the S. aureus 
isolates (7, 18). Extensive susceptibility testing was performed in Cape Town where most 
MSSA isolates were susceptible to the majority of antibiotics against which they were 
tested, including cloxacillin, vancomycin, fusidic acid, moxifloxacin, linezolid, teicoplanin 
and tigecycline (7).  However, some MSSA isolates were found to be resistant to 
clindamycin, erythromycin, co-trimoxazole, ciprofloxacin, gentamicin and rifampicin (7). 
Only 6% of  the MSSA isolates were susceptible to penicillin (7).Most MRSA isolates 
displayed multidrug resistance, defined as non-susceptibility to at least three classes of 
antibiotics, however they were all sensitive to vancomycin (7). Clindamycin resistance 
rates were noted to be high in Cape Town and KwaZulu-Natal (7, 18). 
 
1.8 OUTCOMES OF S. AUREUS INFECTION 
Mortality rates associated with S. aureus infections were found to vary in developed and 
developing countries, with higher mortality rates (8.8 to 24.7%) occurring in developing 
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countries (2, 12, 13, 15). Lower mortality rates (0.7 to 3.0%) have been described in New 
Zealand, Australia, England and the USA (12, 13, 15). 
 
MRSA has been associated with higher mortality rates than MSSA in developed and 
developing countries (2, 7, 12, 13, 15). At RCWMCH, MRSA accounted for 53% of deaths 
amongst SAB patients, with a case fatality rate of 8.8% over a five year period (7). 
Mortality was substantially higher (24.7%)in Kenya (2). MRSA infection, HIV and 
malnutrition contributed to higher mortality at RCWMCH (7). 
 
 
1.9 SURGICAL INTERVENTION 
A survey of paediatric hospitals in the USA revealed that the incidence of empyema in 
children nearly doubled, from 3.1 to 6.0 per 100 000, between 1997 and 2009 (19).  The 
introduction of video-assisted thoracoscopic surgery (VATS) in the 1990s introduced a 
new minimally invasive approach of debridement  and drainage of the pleural space, 
without the need for thoracotomy (19). 
 
Over the years, there has been an increase in the use of chest tube with fibrinolytics, 
challenging the use of VATS (19, 20). Both procedures were found to have a similar 
outcome, with no evidence of one modality being superior to the other (19, 20). Both 
procedures are available at CHBAH. 
 
1.10 THE ROLE OF ECHOCARDIOGRAPHY 
Infective endocarditis is a dreaded complication of SAB (11).  In a study of paediatric SAB 
conducted in South Africa, the prevalence of definite infective endocarditis was 12% and 
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was frequently associated with congenital heart disease and multiple positive blood 
cultures (21).   
 
CA-MRSA has been increasingly reported recently and has become an emerging 
pathogen of infective endocarditis in adults, but still rarely reported in children (22). A 
case report documented  a previously healthy preschool child without any heart 
anomaly, who developed infective endocarditis and pneumonia with pleural effusion (22).  
Blood cultures on this child repeatedly yielded MRSA until 13 days after commencement 
of a teicoplanin-containing regimen (22).   
 
 
1.11 IMPACT OF INFECTIOUS DISEASE CONSULTATION 
The impact of infectious disease consultation in adults with SAB has been studied (23-25). 
Involvement of infectious disease subspecialists in the care of children with SAB has 
been associated with improved adherence to guidelines, including appropriate and 
targeted investigation, optimal duration of antibiotic therapy and a reduction in 
complicated infection, morbidity and mortality (23-25). 
 
A study conducted in England examined the impact of introducing an infectious disease 
consultation service on the management of SAB in children (26).The findings of the study 
were that patients who had infectious disease consultations were more likely to have 
echocardiography performed, a removable focus of infection identified and to receive a 
longer course of intravenous antibiotic therapy (26). 
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1.12 PANTON-VALENTINE LEUCOCIDIN-POSITIVE S.AUREUS INFECTIONS 
Invasive community-onset staphylococcal disease has emerged worldwide associated 
with PVL toxin (27). Studies have reported an association between PVL genes and 
invasive disease, thus using PVL-positivity as a marker of severity (27).Results from 
observational studies and a metanalysis show that infection with a PVL-positive strain 
does not predict poor clinical outcome for staphylococcal pneumonia, musculoskeletal 
disease, or bacteraemia; but patients with PVL-positive skin and soft-tissue disease are 
more likely to require surgical treatment (27-29). 
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CHAPTER 2 
2.0 AIMS, OBJECTIVES AND METHODS 
2.1. AIM 
The aim of this study was to describe the clinical spectrum and outcomes associated 
with S. aureus infection in children <14 years of age hospitalized at CHBAH, and to 
identify risk factors of developing invasive disease. 
 
2.2. OBJECTIVES 
The objectives of the study were as follows: 
1. To define the spectrum of clinical presentations of S. aureus infections treated at 
CHBAH over a 1 year period, from 01 January to 31 December 2013, in children 
<14 years; 
2. To define the proportion of S. aureus infections that are CA-MRSA and which are 
HA-MRSA in nature; 
3. To describe risk factors for S. aureus infection, CA-MRSA, HA-MRSA and factors 
associated with poor outcome; 
4. To describe the duration of treatment and outcome of S. aureus infection in 
children at CHBAH. 
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2.3. METHODS 
2.3.1. STUDY DESIGN 
This was a retrospective, descriptive analysis of hospital records. All positive fluid 
cultures on children hospitalised in the general paediatric wards, paediatric surgery and 
burns wards, and neonatal units at CHBAH from 01 January to 31 December 2013 were 
obtained, with permission, from the National Health Laboratory Service (NHLS) 
computerized database. The patients’ clinical data and demographic characteristics (as 
supplied in the laboratory database) were obtained by retrieving and interrogating 
hospital records. Other clinical data were obtained from the Respiratory &Meningeal 
Pathogens Research Unit (RMPRU) computerized database.  
 
2.3.2. STUDY POPULATION 
The study population included all children <14 years of age who had a positive culture 
for S. aureus from body fluids (blood culture, cerebrospinal fluid, pleural fluid, 
pericardial fluid, pus, tissue culture, synovial fluid, and urine) at CHBAH during the 
study time period. The study cohort included children who were admitted in the general 
paediatric wards, paediatric surgical wards (ENT, surgery, neurosurgery, orthopaedic), 
paediatric haematology-oncology wards, neonatal unit and paediatric intensive care 
unit. There were no exclusion criteria. 
 
2.3.3. ETHICAL CONSIDERATIONS 
Although patient identifiers (name and hospital number) were required for retrieval of 
hospital folders and data capture, these were deleted from the database on which all 
analyses were conducted. Ethics approval was obtained from the University of the 
Witwatersrand Committee for Research of Human Subjects (Ethics Clearance Certificate 
number: M140729) (Appendix A). 
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2.3.4. DEFINITIONS 
1. Staphylococcus aureus infection was defined as the isolation of S. aureus from any 
fluid culture specimen, including blood culture, and/or culture from cerebrospinal fluid, 
pleural fluid, pericardial fluid, pus, tissue culture, synovial fluid, and urine, in a child that 
had clinical features of infection. 
2. MRSA was defined as S. aureus resistant to methicillin or cloxacillin on laboratory 
testing. 
3. CA-MRSA was defined as MRSA isolated from a patient in the outpatient environment, 
or within 48 hours of hospitalization, with no prior history of HA-MRSA infection, 
hospitalization, indwelling device, or residence in a long-term care facility. 
4. HA-MRSA was defined as MRSA isolated from a patient beyond 48 hours into a 
hospitalization episode; or MRSA isolated from admission blood cultures in children 
who had prior hospitalization, indwelling devices, a prior history of HA-MRSA infection, 
or who were resident in long-term care facilities. 
5. Malnutrition was classified according to the WHO growth standards. Moderate 
malnutrition was defined as weight-for-height between -2 and -3 standard deviations 
(SD) below the mean. Severe malnutrition was defined as weight-for-height less than -3 
SD below the mean, or the presence of oedema (30). 
6.  HIV infection was confirmed by the presence of a positive HIV PCR in children less 
than 18 months of age, and a positive HIV ELISA in children above 18 months of age. 
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2.3.5. DATA COLLECTION 
All positive S. aureus fluid cultures for the study period were obtained from the NHLS 
computer database, with permission. Data obtained from the NHLS also included the 
antimicrobial susceptibility profiles of the isolates. The demographic and clinical data of 
the patients were obtained by retrieving and interrogating hospital records. All 
information was captured on a standardised data collection sheet (Appendix C). 
Additional patient information was obtained from the RMPRU computerized database 
and the electronic patient management system used by the hospital (Medicom).  
Information captured on the data collection sheet included: 
Demographic information: gender, age, date of birth, place of residence, date of 
hospitalization and date of outcome.  
Clinical outcome: The outcome was classified as discharged, demised, refused hospital 
treatment or transferred to another hospital. 
Clinical data: HIV status, nutritional status, co-morbid disease, presence/absence of an 
indwelling device, ward to which admitted, history of previous hospitalization, clinical 
presentation, and whether or not the patient was admitted to the intensive care unit. 
Treatment (Medical and Surgical): Information on inpatient and outpatient 
antimicrobial therapy and duration of therapy. Surgical interventions of particular 
interest included intercostal drain insertion, VATS, incision and drainage and 
laparotomy. 
Antimicrobial susceptibility: Information on antimicrobial susceptibility was 
obtained. These antimicrobials included; cloxacillin, fusidic acid, amoxicillin-clavulanate, 
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erythromycin, azithromycin, clindamycin, trimethoprim-sulfamethoxazole, amikacin, 
gentamicin, cefotaxime/ceftriaxone, linezolid, vancomycin, ciprofloxacin and rifampicin.  
 
2.3.6. STATISTICAL ANALYSIS 
Data were captured on a customized data collection sheet (Appendix C) and entered into 
Microsoft Excel for analysis. Data were interpreted by means of frequency tables, 
graphs, percentages and SD using Microsoft Excel and Stata version 12.0 (SataCorp, 
College Station, Texas, USA).  
Descriptive statistics presented continuous variables as means and SD for normally 
distributed data, and as medians with interquartile ranges (IQR) for skewed data. For 
normal data, the Student’s t-test was used to compare means; for skewed data, the 
Mann-Whitney U test was used to compare medians. A two-sided p-value <0.05 was 
considered significant. 
Risk factors for S. aureus infection were deduced by performing univariate and 
multivariate analyses. Odds ratios and 95% confidence intervals (95%CI) were used to 
describe disease risk factors. 
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CHAPTER 3 
3.0 RESULTS 
Between January and December 2013, 422 episodes of S. aureus infection were 
identified amongst paediatric patients <14 years of age treated at CHBAH.  Of the 422 
patients, 342 (81%) had MSSA and 80(19%) had MRSA; ward of origin and antibiotic 
susceptibility profile data were available for all clinical isolates. Sections 3.1 (specimen 
which cultured the isolate), 3.2 (ward of origin) and 3.3 (antimicrobial susceptibility 
pattern) highlight the results of the analyses done on the full complement of 422 
patients in whom S. aureus was isolated from clinical specimens.  
Clinical data was obtained for 286 (67.7%) patients (Figure 3.1). The subsequent 
analyses (Sections 3.4 through 3.10) highlight the results of the analyses done on the 
286 patients who had both NHLS data and retrievable clinical folders (Figure 3.1). 
 
 
 
Abbreviations: MSSA= methicillin-susceptible S. aureus; MRSA= methicillin-resistant S. aureus 
FIGURE 3.1 DISTRIBUTION OF S. AUREUS EPISODES 
 
286 (67.8%) with available  clinical data included in analyses 
226 (79.0%) MSSA 60 (21.0%) MRSA
136 (32.2%) Irretrievables folders
(Unknown nutritional status, HIV status, clinical presentation, co-morbidities and 
antibiotic management). Excluded from analyses
422 Children with S. aureus infections
342 (81%) MSSA 80 (19%) MRSA
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Table 3.1 highlights the comparison of clinical characteristics between children with S. 
aureus infection whose clinical data were retrievable through review of clinical folders, 
and those whose clinical folders were not available for review. There were no 
statistically significant differences between the groups, indicating that the sub-group of 
286 on which most of the analyses have been based, is likely to be a representative 
sample of all of the children from whom S. aureus was isolated during the study period. 
 
Table 3.1 Comparison of the characteristics of the 422 children with the 286 children with 
available folders 
 
 All 
children  
(n=422) 
Children with available 
hospital folders 
(n=286) 
P- 
value* 
Median age in 
months (IQR) 
 
16.1   
(1.0–75.4) 
 
11.3  (0.6–60.3) 
 
 
0.482^ 
Gender (%) 
Male 
Female 
 
52.1% 
47.9% 
 
55.6% 
44.5% 
 
 
0.365 
0.365 
 
 
Ward of origin (%) 
General Paediatric 
wards 
Surgical 
Neonatal 
Orthopaedic 
Haematology-oncology 
 
 
46.7% 
35.3% 
10.6% 
4.9% 
2.4% 
 
 
 
52.5% 
31.5% 
8.0% 
4.5% 
3.5% 
 
 
0.132 
0.261 
0.245 
0.793 
0.375 
 
MRSA (%) 
MSSA (%) 
19.0% 
81.0% 
21.0% 
79.0% 
0.508 
0.508 
 
 
* P-values derived using Pearson Chi-Square test, unless otherwise stated 
^ Mann-Whitney test used to compare medians 
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3.1 SITE OF S. AUREUS CULTURE 
The site of S. aureus culture was known for all 422 isolates (Fig 3.2).  Of the 422 isolates, 
226 (53.6%) cultured S. aureus from pus, 149 (35.3%) from blood, 20 (4.7%) from 
sputum, 17 (4%) from cerebrospinal fluid, 8 (1.9%) from urine and 2 (0.5%) from 
pleural fluid (Fig 3.2).  
 
 
FIGURE 3.2 SITE OF S. AUREUS CULTURE 
 
3.2 WARD OF ORIGIN 
The ward of origin was known for all the 422 S. aureus isolates. Of the 422 patients, 212 
(50.2%) originated from the general paediatric wards, 134 (31.8%) from the paediatric 
surgical wards (general surgery, neurosurgery and ENT) and burns unit, 45 (10.7%) 
from the neonatal unit, 21 (4.9%) from the orthopaedic ward and 10 (2.4%) from the 
haematology-oncology ward (Figure 3.3, page 32). 
Site of culture (n=422)
PUS
BLOOD
SPUTUM
CEREBROSPINAL FLUID
URINE
PLEURAL FLUID
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Most (188/342: 55%) MSSA isolates were from patients treated in the medical wards, 
whereas the majority of MRSA isolates (48/80: 60%) were from patients managed in the 
surgical setting. Children treated in the surgical wards and neonatal unit had a 4.5-fold 
(95% CI, 2.69-7.41) and 5.2-fold (95% CI, 2.77-10.1) greater odds of having MRSA rather 
than MSSA infection, respectively (Table 3.5, page 40). Forty (83.3%) of the 48 children 
diagnosed as having MRSA infection in the surgical wards, were being treated in the 
burns unit. 
 
FIGURE 3.3 WARD OF ORIGIN OF THE S. AUREUS EPISODES 
 
3.3 ANTIMICROBIAL SUSCEPTIBILITY 
Data relating to antimicrobial susceptibility were available for all 422 S. aureus isolates. 
The MSSA isolates were susceptible to most antimicrobials against which they were 
tested. These antimicrobials included cloxacillin, fusidic acid, amoxicillin-clavulanate, 
erythromycin, azithromycin, clindamycin, trimethoprim-sulfamethoxazole, amikacin, 
gentamicin, cefotaxime/ceftriaxone, linezolid, vancomycin, ciprofloxacin and rifampicin. 
Ward of Origin (n=422)
General Paediatric Wards
Surgical Ward
Neonatal Unit
Orthopaedic ward
Haematology-Oncology Wards
33 
 
Three (1.1%) MSSA isolates were sensitive to penicillin and 5 (1.9%) were sensitive to 
ampicillin. All of the MRSA isolates were susceptible to vancomycin (Table 3.2). 
Table 3.2 Antimicrobial susceptibility results for all 422 S. aureus isolates 
Antibiotic MSSA (n=342) 
Number of susceptible 
isolates/number tested (%) 
MRSA (n=80) 
Number of susceptible 
isolates/number tested (%) 
Penicillin 3/267 (1.1%) 0/59 (0%) 
Ampicillin 5/267 (1.9%) 0/59 (0%) 
Cloxacillin 342/342 (100%) 0/80 (0%) 
Erythromycin/Azithromycin 33/33 (100%) 2/19 (10.5%) 
TMP/SMX 29/32 (90.6%) 1/14 (7.1%) 
Vancomycin 3/3 (100%) 80/80 (100%) 
Ciprofloxacin 3/3 (100%) 1 /4 (25%) 
Gentamicin 1/1 (100%) NT 
Rifampicin 1/1 (100%) NT 
Fusidic acid 6/6 (100%) NT 
Clindamycin 30/30 (100%) 2/6 (33.3%) 
Linezolid 2/2 (100%) 2/2 (100%) 
Cefotaxime/ceftriaxone 1/1 (100%) NT 
Chloramphenicol 
Amoxicillin-clavulanate 
6/6 (100%) 
15/15 (100%) 
0/4 (0%) 
1/3 (33.3%) 
Abbreviations: NT= Not tested; TMP/SMX = Trimethoprim-sulfamethoxazole 
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3.4. CHARACTERISTICS OF CHILDREN WITH S. AUREUS INFECTION 
The median age of the 286 patients from whom S. aureus was isolated was 11.3 months 
(IQR 0.6-60.3 months) (Table 3.3, page 39). There were 159 (55.6%) boys and 127 
(44.5%) girls, with a male to female ratio of 1.25:1. 
  
3.4.1 HIV INFECTION STATUS 
Of the 286 patients, 165(57.7%) patients were HIV-negative, and 36(12.6%) were HIV-
positive. Eighty-five (29.7%) of the 286 patients had undefined HIV infection status 
(Figure 3.4). Of the 36 patients who tested HIV- positive, 13 (36%) had MRSA (Figure 
3.4). 
In patients with MSSA, (143/226, 63.3%) tested HIV-negative, 23 (10.2%) were HIV-
positive and 60(26.5%) had undefined HIV status. Thirteen (21.7%) of the 60 children 
with MRSA infection were HIV positive (Table 3.3, page 39). 
 
FIGURE 3.4 HIV INFECTION STATUS OF CHILDREN WITH S.AUREUS INFECTION 
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3.4.2 ANTIRETROVIRAL THERAPY 
Nineteen (52.8%) of the 36 patients who were HIV-positive were on antiretroviral 
therapy.  The date of initiation of antiretroviral therapy could be determined for all of 
the 19 patients who had been on treatment. Fourteen of the 19 (73.7%) patients had 
been on antiretroviral therapy for more than 6 months, while the remaining 5 (26.3%) 
patients were on antiretroviral therapy for less than 6 months (Figure 3.5). 
 
 
FIGURE 3.5 ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS 
 
3.4.3 NUTRITIONAL STATUS 
Nutritional status could be determined for 147 (51.3%) of the 286 patients included in 
the analysis. Of the 147 patients with determined nutritional status, 84 (57.1%) had 
normal nutritional status, 45 (30.6%) were severely malnourished and 18 (12.2%) were 
moderately malnourished according to the WHO classification (Figure 3.6, page 36).  
Duration of Antiretroviral Therapy
< 6 months: 5/19 (26.3%) > 6 months: 14/19 (73.7%)
Antiretroviral Therapy
Yes: 19/36 (52.8%) No: 17/36 (47.2%)
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FIGURE 3.6 NUTRITONAL STATUS OF CHILDREN WITH S.AUREUS INFECTION 
 
3.4.4 SETTING IN WHICH S. AUREUS INFECTION WAS ACQUIRED 
Two-hundred and nine (73.1%) of the 286 patients with available demographic and/or 
clinical data had community-acquired infections and 72 (25.2%) had hospital-acquired 
infections (Figure 3.7, page 37). Of the 208 patients who had community-acquired 
infections, 203 (97.6%) had MSSA. Five (2.4%) of the 208 children deemed to have 
community-acquired infections had infection caused by MRSA, and were therefore 
classified as having CA-MRSA. Clinical and/or demographic data was obtainable for 3 
(60%) of the 5 children with CA-MRSA (Table 3.4, page 40). Of the 72 patients who had 
hospital-acquired infections, 56 (77.8%) had MRSA and 16 (22.5%) had MSSA (Figure 
3.8, page 37).   
Six (2.1%) of the 286 children with available demographic and/or clinical data had S. 
aureus infections which could not be classified in terms of whether they were 
community- or hospital-acquired. This was because the dates of hospitalisation were 
unknown for these patients, thus the timing of sample collection in relation to 
hospitalisation could not be determined. Of these six children, 4 (66.7%) had MSSA and 
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2 (33.3%) had MRSA. HIV status was documented for 6 of these patients, and all were 
HIV-negative. 
 
Abbreviations:  MSSA= methicillin-susceptible S. aureus; MRSA= methicillin-resistant S. aureus  
FIGURE 3.7 DISTRIBUTION OF MSSA AND MRSA EPISODES 
 
FIGURE 3.8 PLACE OF ACQUISITION OF INFECTION OF THE S. AUREUS EPISODES 
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3.4.5 DURATION OF HOSPITALISATION 
Of the 286 patients with available demographic and/or clinical data, the median 
duration of hospital stay was 11 days (IQR 5-24 days). The duration of hospital stay was 
significantly longer (35 days; IQR 24-65 days) in those with MRSA infection compared to 
those with MSSA infection (8 days; IQR 4-18 days), p<0.001 (Table 3.3, page 39). 
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Table 3.3 Characteristics of the 286 patients with available demographic/clinical data 
 All 
(n=286) 
MRSA 
(n=60) 
MSSA 
(n=226) 
p-value* 
 
Age in months (median, IQR) 
 
Age stratification 
<1 month 
1-11 months 
>12 months 
 
Gender 
Male 
Female 
 
 
 
11.3                       
(0.6–60.3) 
 
69 (24.1%) 
72 (25.2%) 
145 (50.7%) 
 
 
159 (55.6%) 
127 (44.5%) 
 
19.8 
(0– 56.1) 
 
20 (33.3%) 
10 (16.7%) 
30 (50.0%) 
 
 
36 (60.0%) 
24 (40.0%) 
 
9.5 
(0.73– 60.9) 
 
49 (21.7%) 
62 (27.4%) 
115 (50.9%)  
 
 
123 (54.4%) 
103 (45.6%) 
 
0.471   
 
 
  0.061 
  0.088 
  0.903 
 
 
  0.439 
  0.439 
 
 
Nutritional status (n=147) 
Severe Malnutrition 
Moderate Malnutrition 
Normal 
 
 
 
45/147 (30.6%) 
18/147 (12.2%) 
84/147 (57.1%) 
 
 
16/37(43.2%) 
2/37 (5.4%) 
19/37 (51.4%) 
 
 
29/110 (26.4%) 
16/110 (14.5%) 
65/110 (59.0%) 
 
 
<0.001 
   0.288 
   0.660 
 
HIV Infection 
HIV-positive 
HIV-negative 
HIV-unknown 
 
 
36 (12.6%) 
165 (57.7%) 
85 (29.7%) 
 
 
13 (21.7%) 
22 (36.7%) 
25 (41.7%) 
 
 
23 (10.2%) 
143 (63.3%) 
60 (26.5%) 
 
 
  0.017 
<0.001 
  0.023 
Place  of residence 
Long term facility 
Home 
 
15 (5.2%) 
271 (94.8%) 
 
11 (18.3%) 
49 (81.7%) 
 
4 (1.8%) 
222 (98.2%) 
 
<0.001 
<0.001 
 
Indwelling device 44 (15.4%) 28 (46.7%) 16 (7.1%) <0.001 
 
Co-morbidities 
 
 
 
 
 
  
Prematurity 30 (10.5%) 15 (25.0%) 15 (6.6%) <0.001 
Tuberculosis 17 (5.9%) 2 (3.3%) 15 (6.6%)   0.539  
Congenital 
Heart Disease 
6 (2.1%) 1 (1.7%) 
 
5 (2.2%)   1.000^ 
Chronic 
Kidney Disease 
1 (0.4%) 0 (0.0%) 1 (0.4%) 
 
  1.000^ 
Malignancies 7 (2.5%) 1 (1.7%) 6 (2.7%)   1.000^ 
Burns 40 (13.9%) 29 (48.3%) 11 (4.9%) <0.001 
No co-morbidity 185 (64.7%) 12 (20.1%) 173 (76.5%) 
 
<0.001 
Duration of stay (median, IQR) 11 (IQR 5–24) 35 (IQR 14-65) 8 (IQR 4-18) <0.001 
     
Place of infection 
HA 
CA 
 
72 (25.7%) 
208 (74.3%) 
 
54 (90%) 
5 (8.3%) 
 
18 (7.9%) 
203 (89.8%) 
 
<0.001 
<0.001 
Unknown 
 
Previous Hospital Admission 
 
ICU Admission 
6 (2.1%) 
 
42 (14.7%) 
 
48 (16.8%) 
1 (1.7%) 
 
7 (11.7%) 
 
30 (50.0%) 
5 (2.2%) 
 
35 (15.5%) 
 
18 (7.9%) 
  1.000^ 
 
  0.457 
 
<0.001 
* P-values derived by using the Mann Whitney test (comparing medians) and Pearson Chi-Square test 
(comparing proportions), comparing the MRSA and MSSA groups, used unless otherwise indicated. 
^ Fisher’s exact test. Abbreviations: CA = community-acquired; HA = hospital-acquired; ICU = intensive 
care unit; MRSA = methicillin-resistant S. aureus; MSSA = methicillin-susceptible S. aureus. 
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Table 3.4 Clinical characteristics of children with CA-MRSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5 Comparison of MRSA and MSSA infection in respective wards for all 422             
S. aureus isolates 
Ward  MSSA (N=342) MRSA (N=80) OR (95%CI)* p-value 
Paediatric 
medical 
203 (59.4%) 9 (11.3%) 0.09 (0.04-0.18) <0.001 
Paediatric 
surgical  
86 (25.1%) 48 (60%) 4.47 (2.69-7.41) <0.001 
Paediatric 
orthopaedic 
21 (6.1%) 0 - 0.019 (exact) 
Haematology-
oncology 
9 (2.6%) 1 (1.3%) 0.47 (0-2.92) 0.695 (exact) 
Neonatal Unit 23 (6.7%) 22 (27.5%) 5.23 (2.77-10.10) <0.001  
* Comparisons reflecting the odds of having MRSA rather than MSSA infection in each of the 
ward settings. 
 
 
 PATIENT 1 PATIENT 2 PATIENT 3 
Age 2 months 4 months 55 months 
Gender Male Male Male 
HIV Status Positive Negative Negative 
Nutritional status Normal Normal Normal 
Co-morbidities No defined  
co-morbidity 
No defined co-
morbidity 
No defined co-
morbidity 
 
Clinical presentation 
 
 
 
 
Antibiotic choice 
 
 
Duration of treatment 
 
 
Pneumonia 
 
 
 
 
Amoxicillin-
Clavulanate 
 
7 days 
 
 
Skin and soft 
tissue infection 
 
 
 
Cloxacillin 
 
 
21 days 
 
 
Septic wound 
 
 
 
 
Vancomycin 
 
 
10 days 
Outcome Discharged Discharged Discharged 
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3.5. SPECTRUM OF CLINICAL PRESENTATION FOR CHILDREN WITH S. AUREUS 
INFECTION 
One-hundred and seven (37.4%) of the 286 patients with available clinical information 
presented with SSTI, which was the commonest clinical presentation amongst those 
with MSSA infection. Thirty-four (11.9%) patients presented with pneumonia, two 
thirds (23/34, 67.6%) of which had MSSA infection (Table 3.6, page 42).  
Twenty-nine (10%) patients had bacteraemia without a focus. Seventeen (5.9%) 
patients presented with meningitis and 13 (4.5%) presented with bone and joint 
infections. MSSA was significantly associated with SSTI, whereas MRSA was associated 
with septic (surgical/burns) wounds (Table 3.6, page 42). All bone and joint infections 
were associated with MSSA. The commonest clinical presentation for CA-infection was 
SSTI, and children with HA-infection presented mainly with septic (surgical/burns) 
wounds and bacteraemia without focus (Table 3.7, page 43). 
 Other clinical presentations included: urinary tract infections in 8 (2.8%), conjunctivitis 
in 6 (2.1%), STSS in 5 (1.7%), acute gastroenteritis in 4 (1.4%), SSSS in 3 (1.0%), and 
empyema in 2 (0.7%). All of these less common clinical presentations were associated 
with MSSA. One (0.3%) patient presented with infective endocarditis, which was a HA-
infection associated with MRSA (Table 3.7, page 43). 
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Table 3.6 Spectrum of clinical presentation for the 286 patients with available   
folders 
Clinical Spectrum All patients 
MRSA 
(n=60) 
MSSA 
(n=226) 
p-value* 
 
 
 
SSTI 
 
 
 
107 (37.4%) 
 
 
5 (8.3%) 
 
 
102 (45.1%)         
 
 
 
<0.001 
 
Septic wounds 
 
 
39 (13.4%) 
 
 
25 (42.4%) 
 
 
14 (6.2%)            
 
 
    <0.001 
 
Pneumonia 
 
 
34 (11.9%) 
 
 
11 (18.5%) 
 
 
23 (10.2%)                
 
 
0.083 
 
Bacteraemia without a focus 
 
 
29 (10.1%) 
 
 
6 (10.2%) 
 
 
23 (10.2%)                       
 
 
0.968 
 
 
      0.336 
 
 
Meningitis 
 
17 (5.9%) 
 
2 (3.3%) 
 
15 (6.7%)                      
 
 
Bone and joint infections 
 
 
13 (4.6%) 
 
 
2 (3.4%) 
 
 
11 (4.9%)                 
 
 
      0.612 
 
 
  0.211^ 
 
      0.349^ 
 
Urinary tract infection 
 
 
8 (2.8%) 
 
 
0 (0.0%) 
 
 
8 (3.6%) 
 
Conjunctivitis 
 
6 (2.1%) 
 
0 (0.0%) 
 
6 (2.7%) 
 
 STSS 
 
5 (1.8%) 
 
2 (3.4%) 
 
3 (1.3%) 
 
      0.282^ 
 
     1.000^  
 
     1.000^ 
Acute gastroenteritis 
 
4 (1.4%) 
 
1 (1.7%) 
 
3 (1.3%)          
 
 SSSS 
 
3 (1. 1%) 
 
0 (0.0%) 
 
3 (1.3%) 
 
Omphalitis 
 
3 (1.1%) 
 
2 (3.3%) 
 
1 (0.4%) 
 
      0.112^ 
 
Empyema 
2 (0.7%) 
 
0 (0.0%) 
 
2 (0.9%) 
 
      1.000^ 
Endocarditis 
 
1 (0.4%) 
 
 
1 (1.7%) 
 
 
0 (0.0%)           
 
 
    0.209^ 
 
 
Others 
 
9 (3.2%) 4 (6.8%) 5 (2.2%)                        
 
0.096^ 
 
      0.349^ Unknown    6 (1.4%) 0 (0.0%) 6 (1.8%)  
 
* P-values derived using Pearson Chi-Square test, unless otherwise stated, comparing the MRSA and MSSA 
groups.                                                                                                                                                                                             
^ Fisher’s exact test                                                                                                                                                 
Abbreviations: SSSS = staphylococcal scalded skin syndrome; SSTI = skin and soft tissue infection; STSS = 
staphylococcal toxic shock syndrome. 
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Table 3.7 Clinical presentation of community-acquired and hospital-acquired S. aureus 
infections in 280 children whose place of acquisition of S. aureus infection could be 
determined 
Clinical Presentation All Community-acquired 
(n=209) 
Hospital-acquired 
(n=71) 
p-value* 
 
 
 
 
 
 
 
 
 
SSTI 
 
107 (37.4%) 
 
100 (47.9%) 
 
7 (9.9%) 
 
<0.001 
Septic wounds 
 
Pneumonia 
39 (13.4%) 
 
34 (11.9%) 
8 (3.8%) 
 
21 (10.1%) 
31 (43.7%) 
 
13 (18.3%) 
<0.001 
 
 0.066 
 
Bacteraemia with a focus 
 
 
29 (10.1%) 
 
16 (7.7%) 
 
13 (18.3%) 
 
 0.011 
 
Meningitis 
 
17 (5.9%) 15 (7.2%) 2 (2.8%)   0.184 
Bone and joint infections 
 
13 (4.6%) 11 (3.9%) 2 (2.8%)   0.397 
Urinary tract  infections 
 
8 (2.8%) 8 (3.8%) 0 (0.0%)   0.209^ 
Conjuctivitis 
 
6 (2.1%) 6 (2.8%) 0 (0.0%)   0.343^ 
STSS 
 
5 (1.8%) 3 (1.4%) 2 (2.8%)   0.604^ 
Acute gastroenteritis 
 
4 (1.4%) 4 (1.9%) 0 (0.0%)   0.575^ 
SSSS 
 
3 (1.0%) 3 (1.4%) 0 (0.0%)   0.574^ 
Omphalitis 
 
3 (1.1%) 3 (1.4%) 0 (0.0%)   0.574^ 
Empyema 
 
2 (0.7%) 2 (0.9%) 0 (0.0%)   1.000^ 
Endocarditis 
 
1 (0.4%) 0 (0.0%) 1 (1.4%)   0.254^ 
Others$ 9 (3.2%) 9 (4.3%) 0 (0.0%)   0.112^ 
* P-values derived using Pearson Chi-square test, unless otherwise stated, comparing the MRSA and MSSA 
groups; 
^ Fisher’s exact; 
$ Others = Bursitis (n=5), dacrocystitis (n=4); 
Abbreviations: SSSS = staphylococcal scalded skin syndrome; SSTI = skin and soft tissue infection; STSS = 
staphylococcal toxic shock syndrome. 
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3.6. RISK FACTORS FOR MRSA INFECTION 
Univariate and multivariate analyses were done to determine risk factors for MRSA 
infection. Univariate analysis showed that severe malnutrition, being a resident of a long 
term facility, presence of an indwelling device, prematurity, burns, treatment in the 
intensive care unit (ICU), hospital-acquired infection and prolonged hospitalization 
were risk factors for MRSA infection. In the multivariate analysis model, only acquisition 
of infection in hospital retained its significance as a risk factor for MRSA infection  
(Table 3.8).   
Table 3.8 Risk factors for MRSA infection for the 286 patients with available folders 
RISK FACTORS  Univariate Analysis  Multivariate Model# 
 OR* (95% CI) aOR^ (95% CI) 
Moderate Malnutrition  2.50 (0.42 – 14.83)  
Severe Malnutrition  
 
 
HIV–positive 
11.03 (3.41 – 35.74) 
 
 
1.54 (0.46 - 5.13) 
 
 
Long term facility 
resident  
12.46 (3.81 – 40.77)  
Indwelling device  12.08 (5.86 – 24.90)  
Prematurity  14.42 (5.72 – 36.34)  
Burns  38.01 (15.33 – 94.21)  
Duration of hospital stay 1.02 (1.01 – 1.03) 1.01 (0.99 – 1.02)  
ICU Admission  11.22 (5.60-22.45)  
Place of infection 
(hospital)  
99.62 (37.68 – 263.36) 125.55 (11.67 – 1350.68)  
* OR = Odds ratio; ^aOR = Adjusted odds ratio. # The multivariate model adjusted for HIV status, 
nutritional status, comorbidities, place of residence, place of infection, duration of hospital stay, and 
presence of an indwelling device. 
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3.7 ANTIBIOTIC MANAGEMENT FOR THE 286 PATIENTS WITH AVAILABLE FOLDERS 
Antibiotic management was determined for 250 (87.4%) of the 286 patients with 
available demographic and/or clinical data. One hundred and eighty-six (78.4%) of 
these patients had community-acquired infection and 64 (21.6%) had hospital-acquired 
infection.  
There were 28 (43.8%) patients who had septic wounds and cultured S. aureus on pus 
swabs, but were systemically well and were not given systemic antibiotic therapy. These 
patients were from the group with hospital-acquired infection and were treated with 
topical antiseptic dressings only. These patients had septic burn wounds and septic drip 
site ulcers and were all based in the surgical wards. 
Data on antibiotic therapy was based on review of prescription charts. Directed therapy 
was mainly cloxacillin, vancomycin, and amoxicillin-clavulanate. Beta-lactam antibiotics 
were commonly used for the empiric therapy of community-acquired infections. Of the 
186 patients who had community-acquired infections, 101 (54.3%) were treated with 
cloxacillin alone, 53 (28.5%) were treated with amoxicillin-clavulanate, and 27 (14.5%) 
were treated with a combination of cloxacillin and a third generation cephalosporin. 
Five (2.7%) patients, all of them with persistent S. aureus bacteraemia as evidenced by 
the presence of two or more positive blood cultures, were treated with cloxacillin and 
fusidic acid. 
 
Vancomycin was the antibiotic of choice for the children with hospital-acquired 
infections. This was also based on directed antimicrobial therapy. Thirty-four (53.1%) 
patients with hospital-acquired infections were treated with vancomycin, and 2 (3.1%) 
were treated with linezolid. 
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3.7.1 DURATION OF ANTIBIOTIC THERAPY PER S. AUREUS SYNDROME 
The duration of inpatient and outpatient antibiotic treatment varied in accordance with 
the clinical diagnosis.  Patients with bone and joint infections (n=13) and infective 
endocarditis (n=1) were treated for a median of 6 weeks (IQR, 3–8 weeks). Children 
with meningitis (n=17) were treated for a median of 3 weeks (IQR, 2–6 weeks).  All 
other groups of S. aureus infection were treated for a median duration of 11 days (IQR 5 
– 24 days). There were 3 patients who had documented persistent SAB who were 
treated with a combination of cloxacillin and fusidic acid. The duration of antibiotic 
therapy in these patients ranged from 14 to 21 days. 
In addition to antibiotic therapy, two patients who presented with empyema had 
intercostal drain insertion, and subsequently underwent VATS. 
 
3.8 OUTCOME 
One-hundred and eighty-nine (90.4%) of the 209 children with community-acquired S. 
aureus infection were discharged, ten (4.8%) were transferred to other hospitals, five 
(2.4%) died, and the parents of one (0.5%) child refused hospital treatment. Of the 5 
patients who died, 3 had sepsis and 2 had bacteraemic pneumonia. The outcome was 
unknown for four (1.9%) patients with community-acquired S. aureus infection. 
Amongst the 71 children with hospital-acquired S. aureus infection, 48 (67.6%) were 
discharged, 17 (23.9%) died, and 4 (5.6%) patients were transferred to other hospitals.  
Of the 17 patients who died, 10 had septic wounds, 4 had bacteraemic pneumonia, 2 had 
SAB and 1 had infective endocarditis. The outcome was unknown for two (2.8%) 
patients with hospital-acquired S. aureus infection. 
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The odds of dying was 13-fold (95% CI, 4.61 to 37.10) greater in children with MRSA 
infection as compared to infection caused by MSSA. 
Four (4/22, 18.2%) of the patients who died, 3 with MRSA and 1 with MSSA infection, 
were not initiated on any antimicrobial therapy before time of death. The remaining 18 
(18/22, 81.8%) patients who died were on antimicrobial therapy for a median duration 
of 6 days (IQR 5- 14 days) before time of death.  
 
 
Table 3.9 Case fatality rates per clinical syndrome for the 17 patients who died 
 
Clinical Syndrome 
 
Number of 
cases 
Number of 
deaths 
Case Fatality Rate 
Infective Endocarditis 
 
1 1 100% 
Septic wounds 
 
39 10 25.6% 
Bacteraemic Pneumonia 
 
34 4 11.8% 
SAB/Bacteraemia without a 
focus 
 
29 2 6.9% 
    
 
 
 
Abbreviations: SAB = Staphylococcus aureus bacteraemia 
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3.9 ADMISSION TO THE INTENSIVE CARE UNIT 
Of the 286 patients with available clinical data, 48 (16.8%) were admitted to ICU, with 
HA-infections accounting for 87.5% of those patients and CA- infections accounting for 
12.5%.  The clinical presentation amongst patients who were admitted to ICU included 
septic wounds (54.2%), pneumonia (25.0%), STSS (8.3%), bacteraemia without a focus 
(6.3%), septic arthritis (4.2%) and infective endocarditis (2.1%). 
 
 
 
 
3.10 RISK FACTORS FOR MORTALITY 
On univariate analysis amongst patients with hospital-acquired infections, the following 
were associated with higher mortality:  malnutrition, infection caused by MRSA, 
haematology-oncologic conditions, and neonates with prematurity. Neonates treated in 
the general paediatric wards appeared to have a better outcome as the majority of them 
were not preterm. On multivariate analysis, acquisition of infection in hospital was the 
only factor independently associated with a higher mortality (Table 3.10, page 49). 
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Table 3.10 Risk factors for mortality 
 
RISK FACTORS  UNIVARIATE MODEL 
 
MULTIVARIATE MODEL# 
 OR* (95% CI)  aOR^ (95% CI)   
Female gender  2.35 ( 0.96 – 5.82)   
Severe Malnutrition  10.25 (2.11 – 49.84)   
Moderate Malnutrition  2.41 (0.21 – 28.13)   
Ward (Haematology-Oncology)  6.90 (1.15 – 41.25)   
Ward (Neonates)  12.08 (3.43 – 42.53)   
MRSA  8.48 (3.36 – 21.40)   
Place of infection (Hospital)  13.09 (4.62 – 37.10)  8.70 (1.55 – 48.77)  
* OR = Odds ratio; ^aOR = Adjusted odds ratio# The multivariate model adjusted for nutritional status, 
comorbidities, place of residence, place of infection, duration of hospital stay and presence of an 
indwelling device. 
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CHAPTER 4 
4.0 DISCUSSION 
Paediatric S. aureus infections are an important cause of morbidity. Most invasive S. 
aureus infections in our setting are caused by methicillin-susceptible strains, although 
MRSA should be considered, particularly in the context of hospitalized patients. 
Community-onset MRSA infections appear to be uncommon in our setting. 
 
4.1 GENDER PREFERENCE 
According to previous publications, S. aureus infections appear not to have a specific 
gender preponderance (7, 9). In this study, there was no significant gender preponderance 
for S. aureus infections, with a male: female ratio of 1.25:1. This is consistent with the 
Cape Town and Canadian studies, which showed male: female ratios of 1.1:1 and 1.3:1 
respectively (7, 9).  
 
4.2 AGE PREFERENCE 
Staphylococcus aureus infections appear to affect different age groups according to the 
different populations studied (7, 9, 10).South African studies show a predilection of S. 
aureus infections in the younger age groups, whereas international studies show a 
predilection of older children (7, 9, 10). In this study, the median age was 11.3 months (IQR 
0.6 - 60.3); which was similar to that observed in a Cape Town study of SAB, in which the  
median age was 11.3 months (IQR 3.8 - 42.3) (7). In New Zealand, the mean age was 74 
months (0.25 - 168 months); and in Canada the median age was 6.6 years (IQR 1.0 - 11.2 
years ) (9, 10). The reason for the age difference can be explained by the social 
determinants of health which affect developing countries.  
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4.3 RISK OF MRSA 
 
Increasing rates of MRSA infection have been observed in England and in the USA (31, 32). 
There has been an upward trend of MRSA infection over the past four decades, from 2% 
in 1974, to 18% in 1992, and 26% in the study done in Cape Town (7, 31, 32). In the current 
study, 19% of patients had MRSA infections.  A large proportion (88%) of the MRSA 
isolates were nosocomial or healthcare associated. As reported in other studies, MRSA 
appears to be common in neonates and infants as compared to the older age group (31, 
33). 
 
A study in the USA looked at the reasons why neonates are particularly vulnerable to 
colonization and infection with MRSA, and identified  low birth weight, prematurity and 
multiple gestations to be important risk factors (34). Procedures and devices, such as 
endotracheal intubation, mechanical ventilation, percutaneous central venous 
catheterization and surgery, that neonates in ICU often required during their hospital 
stay were also found to be associated with higher risk of MRSA infection(34).  Feeding 
methods, including gavage feedings and receipt of parenteral nutrition have also been 
associated with a higher risk of MRSA infection (34). 
 
In this cohort, children treated in the surgical and neonatal wards had a 4.5 and 5.2-fold 
greater odds of having S. aureus infection caused by MRSA, rather than MSSA (Table 3.5, 
page 40). These findings are similar to the findings from Cape Town, which showed 
increased rates of MRSA infection in patients with prolonged hospitalization(7).The most 
common presentation of MRSA infection in the current study was that of septic surgical 
and burn wounds (Table 3.7, page 43). 
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Other South African studies have shown higher rates of  MRSA in children who are HIV-
positive (7, 14). In this cohort, 36% of patients who were HIV-positive had MRSA, 
compared to 13% of HIV-negative children that had MRSA, but on multivariate analysis, 
HIV infection was not seen to be a risk factor for MRSA infection (Table 3.8, page 44). 
The reason for the different findings in this study as compared to other studies could be 
due to the number of patients with unknown HIV status. In this study, 47.2% of patients 
were not on any antiretroviral therapy. Most of the patients who were not on any 
antiretroviral therapy were not eligible for initiation of treatment, as per the national 
guidelines for the initiation of antiretroviral therapy at the time. However, more than 
50% of patients were on antiretroviral therapy. The new guidelines for initiating 
antiretroviral therapy are: all children less than 5 years of age; children between 5 and 
10 years of age with WHO stage 3 or 4 disease (irrespective of CD4 count), or CD4 count 
less or equal to 500 (irrespective of WHO stage).   
 
In Cape Town, 20% of patients were HIV- positive and of those patients, 49% had MRSA 
bacteraemia (7).The reason for the higher proportions of MRSA in HIV-infected children 
is thought to be due to the fact that they are more often hospitalised compared to 
immunocompetent children, and are therefore at risk of being colonised with 
nosocomial pathogens harbouring antibiotic resistance (7). 
 
Similar to the Cape Town study, other risk factors associated with MRSA infection on 
univariate analysis included malnutrition, being a resident of a long term facility, 
presence of an indwelling device, prematurity, burns and prolonged hospitalization; 
however, only hospital-acquired infections were associated with MRSA  in the 
multivariate analysis (Table 3.8, page 44).  
53 
 
4.4 SPECTRUM OF CLINICAL PRESENTATION 
Skin and soft tissue infections were the commonest clinical presentation for children 
with MSSA in this study, accounting for nearly half (45%) of the patients with MSSA 
(Table 3.5 page 40). This was followed by bacteraemic pneumonia (10.2%) and 
bacteraemia without a focus (10.2%). MSSA was significantly associated with SSTI, 
whereas MRSA was associated with septic (surgical/burns) wounds (Table 3.6, page 42). 
All bone and joint infections were associated with MSSA. In Cape Town, the commonest 
clinical presentation was bacteraemia without a source (7). This difference may be 
explained by the fact that the Cape Town study focused on S. aureus bloodstream 
infections, whereas the current study looked at S. aureus cultured from different sites, 
including pus swabs. 
According to this study, pneumonia was a common clinical presentation in 10.2% of the 
patients.  In view of this finding, an antimicrobial with good cover for staphylococcal 
infections should be considered as part of the first line antimicrobial choices for treating 
CA-pneumonia. 
During this study period, 5.9% of patients presented with meningitis. These patients 
were treated with a combination of cloxacillin and a third generation cephalosporin. 
This study did not look at the morbidity associated with meningitis, however, none of 
the patients with meningitis died. The morbidity associated with meningitis, which 
includes the development of hydrocephalus, cerebrovascular accidents, seizures, vision 
and hearing impairment, should be considered as an area of future research. 
 
During this study period, all community-acquired bone or joint infections were caused 
by MSSA isolates, and the most frequently prescribed empiric antibiotic therapy (in 
54 
 
41.4%) was cloxacillin. This is similar to the findings at RCWMCH, where the empiric 
antibiotic of choice for osteomyelitis and septic arthritis was cloxacillin (7). 
 
4.5 PLACE OF ACQUISITION OF S. AUREUS INFECTIONS 
The majority (74.6%) of the patients in this study cohort had community-acquired 
infections, with hospital-acquired infections comprising one quarter of the episodes.  
This is similar to the national and international studies which show that most paediatric 
S. aureus infections are community-acquired (3, 7). 
 
Five (2.9%) of the 209 children with MRSA infection and enough information on which 
to base the place of origin of the infection, were classified as having CA-MRSA. All the 
patients with CA-MRSA who had obtainable clinical/demographic data had a good 
clinical outcome and were discharged from the respective wards. This is similar to a 
meta-analysis conducted on CA-MRSA, which showed a good clinical outcome (27-29). 
 
4.6 ECHOCARDIOGRAPHY IN S. AUREUS INFECTIONS 
One patient was found to have infective endocarditis during the period under review for 
the current study. Echocardiography was not done routinely, but was performed in 
patients who had multiple positive blood cultures and underlying congenital heart 
disease, as per hospital guidelines (36). At RCWMCH, 2.4% of patients were diagnosed 
with endocarditis (7).   According to published data, S. aureus infective endocarditis is a 
life-threatening disease associated with a high rate of complications and a high 
mortality, warranting all patients with SAB to undergo echocardiographic screening in 
order to minimize the risk of missing this potentially lethal diagnosis (11, 21). This study 
did not assess the number of patients who had echocardiography. Assessing the number 
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of SAB patients who have echocardiography will assist in the development of 
standardised universal guidelines for managing patients with SAB and to reduce the 
morbidity associated with S. aureus infective endocarditis. This can be an area of future 
research. 
4.7 ANTIBIOTIC MANAGEMENT 
The antibiotic management was known for 250 patients (87%).  Cloxacillin was the 
preferred antibiotic of choice for the targeted therapy of patients with MSSA in this 
study. Patients treated with cloxacillin were mainly those who presented with SSTI, 
bone and joint infections, pneumonia and bacteraemia without a focus. Patients who had 
meningitis were treated with a combination of cloxacillin and a third generation 
cephalosporin, either cefotaxime or ceftriaxone. Other antibiotics used for the treatment 
of MSSA included amoxicillin-clavulanate, ceftriaxone/cefotaxime, and fusidic acid in 
combination with cloxacillin. The duration of treatment was 6weeks (IQR 3 – 8 weeks) 
for bone and joint infections and infective endocarditis in this study. Patients with 
meningitis were treated for 3 weeks (IQR 2- 6 weeks). The total median duration of 
inpatient treatment for all other groups of S. aureus infection was 11 days (IQR 5-24 
days). According to this study, cloxacillin was the preferred antibiotic of choice for SSTI, 
bone and joint infections, bacteraemic pneumonia and bacteraemia without a focus in 
patients with MSSA, which was similar to the findings in Cape Town (7).  
 
The combination of cloxacillin and fusidic acid was used in patients who had persistent 
bacteraemia or complicated SAB, i.e. patients who had two or more positive blood 
cultures. This was in accordance with the CHBAH guidelines for treating S. aureus 
infections (36). According to the clinical practice guidelines by the Infectious Disease 
Society of America, the use of single agents and combination therapy should be 
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individualized and local epidemiology should be considered when decisions are made 
about antibiotic therapy for S. aureus infections (16). Children with local disease, i.e. skin 
and soft tissue infections, have had good outcomes on single agents, however, some 
groups of patients with invasive disease have benefited from combination therapy (16). 
 
Antibiotic therapy used in the management of this cohort was not documented for 
36(12.5%) of the 286 patients, and a further 27(9.4%) did not receive any antibiotics. 
Children who did not receive antibiotics included those who had septic wounds with S. 
aureus cultured from pus swabs, but were systemically well and were treated with 
antiseptic dressings. Four (4/22, 18.2%) of the patients who were not initiated on any 
antimicrobial therapy demised. The failure of initiation of antimicrobial therapy on 
these patients appears to be the cause of this poor outcome. Reasons for failure to 
initiate appropriate therapy in these patients were not clearly documented. Factors 
affecting appropriate initiation of antimicrobial therapy amongst clinicians should be 
considered as an area of future research.  
 
MRSA was significantly associated with hospital-acquired infections in this cohort, 
which justified the use of vancomycin as the empirical antimicrobial of choice when 
treating healthcare associated infections. Thirty-two (53.3%) of the patients with 
hospital-acquired infection were treated with vancomycin, and two (3.1%) were treated 
with linezolid. The choice of vancomycin as the preferred antimicrobial for the directed 
therapy of hospital-acquired MRSA infections was in accordance with the clinical 
practice guidelines proposed by the Infectious Diseases Society of America (16).  
Clindamycin and linezolid have been recommended in cases of persistent MRSA 
bacteraemia, and in instances where vancomycin treatment fails (15). In this cohort, none 
of the patients with hospital-acquired MRSA were treated with clindamycin (16).  
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In this study, the MSSA episodes were susceptible to most antimicrobials against which 
they were tested. However, similar to findings in Cape Town, there was a high 
prevalence of MSSA strains resistant to penicillin and ampicillin (7). This is in keeping 
with other South African antimicrobial susceptibility studies in children (7, 18, 35). 
 
4.8 OUTCOME OF PATIENTS WITH S. AUREUS INFECTION 
Patients with community-acquired infections had a better outcome compared to those 
who had hospital-acquired infections. Hospital-acquired infections were associated with 
a higher mortality, with a case fatality rate of 24%. In addition, children with hospital-
acquired infections had a 13-fold greater odds of dying compared to those with 
community-acquired infection. The case fatality rate of patients with MSSA infection in 
this study was 2.4%. 
 
The overall case fatality rate in the study was 7.7%, slightly lower in comparison to case 
fatality rates of 8.8% and 8.6% in Cape Town and New Zealand, respectively (7, 10). The 
reason for the lower case fatality rate in this cohort is likely related to the inclusion of 
local cellulitis cases, while other studies focused on the invasive cases. The higher 
mortality in patients with hospital-acquired infections observed in our study is similar 
to findings from other South African studies (6, 7). 
 
Of the 286 patients, 48 (16.8%) were admitted to ICU, with hospital-acquired infections 
accounting for 87.5% of those patients and community-acquired infections accounting 
for 12.5%. Some of the patients might have acquired the infection in ICU, following 
admission for a different pathology that is not caused by S. aureus infection. The findings 
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in this study suggest that hospital-acquired infections are associated with a higher rate 
of ICU admissions, as compared to community-acquired infections. This was not the case 
in a study conducted in New Zealand wherein 94.8% of the children who required 
admission to ICU had community-acquired infection (10). The high rate of ICU admissions 
associated with hospital-acquired infections could be prevented through strict 
adherence to good infection control practice and use of universal precautions. 
  
The outcome of patients after discharge and the number of patients who might have 
returned to hospital after discharge was not known, as this was not part of the 
objectives of this study.  
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CHAPTER 5 
CONCLUSION 
Staphylococcus aureus appears to be a common pathogen in paediatric bacterial 
infections. Most invasive S. aureus infections are caused by methicillin-susceptible 
strains, although MRSA should be considered, particularly in the context of hospitalised 
patients. Community-onset MRSA infections appear to be uncommon in our setting. 
Paediatric S. aureus infections appear to affect different age groups according to the 
different populations studied. South African studies show a predilection of S. aureus 
infections in the younger age groups, whereas international studies show a predilection 
of older children. 
Clinical presentations for MSSA bacteraemia include skin and soft tissue infection, 
pneumonia, meningitis, bone/joint infections and urinary tract infections. Infective 
endocarditis was not a common occurrence in our study, however, it was associated 
with a high mortality.   
Risk factors for MRSA sepsis include burns, prematurity, prolonged hospitalisation, 
presence of indwelling device and malnutrition.  
Children with hospital-acquired infections had a 13-fold greater odds of dying, which 
warrants an urgent need to look at ways to limit infection. These factors include 
addressing the social determinants which predispose patients to burns; good antenatal 
care to reduce prematurity; and adherence to strict infection control practices when 
inserting lines in the ICU setting. 
Cloxacillin or amoxicillin-clavulanate remain the antimicrobials of choice for MSSA, 
whereas vancomycin remains the antimicrobial of choice for MRSA. 
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From this study, it appears that patients with methicillin-susceptible strains have a 
better outcome as compared to those with methicillin-resistant strains. Patients with 
MSSA displayed a good response to cloxacillin or amoxicillin-clavulanate. . 
 
5.1 RECOMMENDATIONS 
 Current practice at CHBAH is for children with SAB to receive 14 days of targeted 
antibiotic therapy, as per international guidelines. 
 Involvement of infectious disease subspecialists in the care of children with SAB 
has been associated with good outcomes and should be practiced across different 
centres. 
 Due to the high mortality associated with hospital-acquired infections, strict 
infection control measures such as handwashing should be emphasized. Strict 
observance of infection control practice would be expected to impact favourably 
on the rates of MRSA infection at our hospital and would be expected to ease the 
pressure on ICU bed occupancy. 
 An improvement in the social determinants of health may contribute to the 
reduction of MRSA through decreasing the numbers of premature infants being 
born and requiring care at the overburdened CHBAH Neonatal Unit, and by 
limiting the numbers of children presenting with burns to the Burns Unit. 
  Good antenatal services will contribute to the reduction of premature deliveries, 
which were associated with an increased risk of MRSA in this study. 
 Neonates receiving care in the Neonatal Unit, or with a history of recently being 
treated in the Neonatal Unit, and residents at long-term care facilities should be 
treated with vancomycin as part of their empiric antibiotic cover for putative 
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MRSA infections, and antibiotic treatment should be rationalised once an isolate 
is cultured and its antibiotic susceptibility profile is determined. 
 The need for invasive lines should be reassessed in the ICU setting and their 
prolonged use should be avoided. 
 All inpatients in both surgical and medical wards should have age appropriate 
HIV testing performed on admission or prior to discharge. 
 
5.2 AREAS FOR FUTURE RESEARCH 
Based on this study, paediatric S. aureus appears to be a common cause of paediatric 
bacterial infections. Although CA-MRSA infections do not appear to cause a large burden 
of disease in our setting, continued surveillance for potential CA-MRSA infection is 
warranted.  
Additional risk factors for complicated SAB should be investigated, in addition to HIV 
infection and malnutrition. This will help in determining the choice of empiric 
antibiotics for patients at risk. The local epidemiology of S. aureus infection should be 
researched further. 
The failure of initiation of antimicrobial therapy resulted in the mortality of some 
patients with S. aureus infection. Factors contributing to the failure of initiation of 
antimicrobial therapy were unclear. Factors affecting appropriate initiation of 
antimicrobial therapy amongst clinicians should be considered as an area of future 
research. 
Very few South African studies have looked at S. aureus infections in the ICU setting; this 
is an area that warrants further research. 
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An update on the prevalence of   S. aureus infective endocarditis in developing countries 
needs to be conducted, which will assist in the development of universal guidelines on 
the role of routine echocardiography in SAB. The current recommendations are based 
on European studies. 
The outcome of patients with S. aureus infection who receive a short duration of 
antimicrobial therapy needs to be researched further. This will assist in more aggressive 
treatment of such patients, with an awareness of the outcome. 
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CHAPTER 6 
LIMITATIONS 
Due to the retrospective nature of this study, there were some limitations. 
 Poor documentation in patients’ hospital folders resulted in a number of patients 
with unknown nutritional status. 
 The lack of availability of clinical folders might have resulted in study bias. 
 The relationship between HIV infection and MRSA could not be established in this
 study as compared to other studies.  This was due to the lack of confirmed HIV     
 status in some patients. 
 Information on the outpatient antibiotic management was not assessed as part  
of this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
APPENDIX A: Chris Hani Baragwanath Academic Hospital Medical Advisory 
Committee Clearance Certificate for this study 
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APPENDIX B: University of the Witwatersrand Human Research Ethics Committee 
(Medical) Clearance Certificate for this study 
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APPENDIX C: Data collection sheet 
 
DATA COLLECTION SHEET 
 
Demographic Information 
File Number: 
Gender: 
Male 
Female 
Date of hospitalization (dd/mm/yy): 
Date of birth (dd/mm/yy):  
Age: 
< 1 month  
1-3 months 
4-11 months 
12-23 months 
24-59 months 
5-14 years  
 
Place of residence: 
At home (i.e. with family)     
At long term Care Facility  
 
Indwelling Device:  Yes  No 
 If Yes, type of device: __________________________________ 
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HIV Status: 
Positive  
Negative  
Unknown       
  
HIV on ART:   Yes   No 
ART start date (dd/mm/yy) 
HIV duration on ART< 6 months   
HIV duration on ART > 6 months 
CD4 count within 3 months of the S. aureus admission episode: 
Date of CD4 count (dd/mm/yy): 
Absolute CD4 count (cells/mm3):        . 
CD4 Percent (%):    . 
 
Nutritional Status (WHO classification): 
Weight (kg):   . 
Height (cm):   . 
Oedema: Yes  No 
Weight-for-height (Z-scores): 
< -2SD  
< -3SD 
  
Co-Morbid Disease: 
Prematurity/ ex-premature 
Congenital Heart Disease 
Tuberculosis 
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Chronic Kidney Disease 
Other 1:        _______________________ 
Other 2:        ________________________ 
Other 3:        ________________________ 
Other 4:        ________________________ 
 
Previous Hospital Admission: 
Yes 
No 
Date of previous Hospital Admission (dd/mm/yy):  
Date of previous Hospital Discharge (dd/mm/yy):   
Diagnosis at previous Hospital Discharge: 
1: ________________________ 
2: ________________________ 
3: ________________________ 
4: ________________________ 
 
Current Hospital Admission: 
Hospital Department in Which Child was treated during the current S. aureus 
hospitalization: 
 Neonatal:  
 Paediatric: 
 Paediatric Surgical:  
 Adult Surgical:  
 Paediatric Orthopaedic:  
 Adult Orthopaedic:  
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 Neurosurgical: 
 Other:     _________________________________ 
Duration of Antibiotics in current admission: 
Date Antibiotics started (dd/mm/yy):  
Date Antibiotics stopped (dd/mm/yy):  
 
Antibiotic 
 
Route Date Started 
(dd/mm/yy
) 
Date 
Completed 
(dd/mm/yy) 
Date 
of culture 
positive 
result 
(dd/mm/yy) 
1. iv / oral    
2. iv / oral    
3. iv / oral    
4. iv / oral    
5. iv / oral    
6. iv / oral    
7. iv / oral    
 
S. aureus Culture Site: 
Blood 
Cerebrospinal Fluid 
Pus 
Pleural fluid  
Urine 
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Other 1:        ________________________ 
Other 2:        ________________________ 
 
 
 
S. aureus antibiotic susceptibility profile: 
Antibiotic Susceptible Intermediate 
resistance 
Resistant E-test Result 
Penicillin     
Ampicillin     
Cloxacillin/ Methicillin     
Amoxicillin-clavulanate     
Cefuroxime     
Cefotaxime/ 
Ceftriaxone 
    
Ciprofloxacin     
Erythromycin     
Clindamycin     
Vancomycin      
Tetracycline     
Rifampicin     
Linezolid     
Daptomycin     
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Clinical Presentation/Diagnosis: 
Pneumonia 
Empyema 
Cellulitis 
Infective Endocarditis 
Meningitis 
Arthritis 
Osteomyelitis 
Staphylococcal Scalded Skin Syndrome 
Other 1:        ________________________ 
Other 2:        ________________________ 
 
Treatment: 
Conservative (antibiotics only): Yes   No 
Surgical: Yes  No 
 If Yes, surgical intervention required: 
Intercostal drain insertion:   Yes   No 
Date ICD inserted (dd/mm/yy):  
Date ICD removed (dd/mm/yy): 
Incision and Drainage:     Yes  No 
Laparotomy:     Yes  No 
Other surgery 1: Yes  No  _________________________ 
Other surgery 2:  Yes  No  _________________________ 
 
 
Intensive Care Admission:    Yes  No 
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Date ICU admission (dd/mm/yy):  
Date ICU discharge (dd/mm/yy):  
 
 
Outcome: 
Date of outcome (dd/mm/yy):  
Discharged home  
Transfer to other hospital 
Refused hospital treatment 
Follow-up 
Demised 
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